Transgenic animal models of tauopathies
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Tauopathies are a group of neurodegenerative disorders that include Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and other related diseases with prominent tau pathology. Research advances in the last several decades have characterized and defined tau neuropathologies of both neuron and glia in these diverse disorders and this has stimulated development of animal models of tauopathies. Indeed, animal models ranging from invertebrate species such as C. elegan to Drosophila melanogaster and mammalian transgenic mouse models of tauopathies have been generated and reported. This review summarizes the salient features of many of the known models of tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 5×
“Hypotheses based on clinical evidence abound, including disrupted axonal transport, toxicity of aggregated tau protein, and the phosphorylation state of tau [19].”
BackgroundInfluentialSelf-citationEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“[21] created mice that produced both the P301L mutant of human tau, JNPL3 mice [21] and mutant APP protein [20].”
BackgroundResultFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Tauopathy in Drosophila : Neurodegeneration Without Neurofibrillary Tangles
Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., & Feany, M. B. (2001) · Science · doi:10.1126/science.1062382 · Cited by 939
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564
Self-citationGenetic modifiers of tauopathy in Drosophila
Shulman, J. M., & Feany, M. B. (2003) · Genetics · doi:10.1093/genetics/165.3.1233 · Cited by 275
Cited by
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
“With a wide range of animal models that partially recapitulate the key phenotypic features of AD and related tauopathies already develope”
BackgroundSelf-citationTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration
Mandelkow, E.-M., & Mandelkow, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006247 · Cited by 847
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
Guo, J. L., & Lee, V. M.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209296 · Cited by 636
Self-citationRole of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects
Barbier, P., Zejneli, O., Martinho, M., Lasorsa, A., Belle, V., Smet-Nocca, C., Tsvetkov, P. O., Devred, F., & Landrieu, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00204 · Cited by 617
The Hexosamine Signaling Pathway: Deciphering the "O-GlcNAc Code"
Love, D. C., & Hanover, J. A. (2005) · Science's STKE · doi:10.1126/stke.3122005re13 · Cited by 461
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Self-citationNEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications
Skovronsky, D. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 425
Self-citationBiomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 339
Self-citationPhysiological and pathological phosphorylation of tau by Cdk5
Kimura, T., Ishiguro, K., & Hisanaga, S.-I. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00065 · Cited by 297
Usenovic, M., Niroomand, S., Drolet, R. E., Yao, L., Gaspar, R. C., Hatcher, N. G., Schachter, J., Renger, J. J., & Parmentier-Batteur, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1523-15.2015 · Cited by 245
“…neuronal loss and deficit of neurite outgrowth that could replicate the neurodegenerative process observed in animal models of tauopathy (Lee et al., 2005; Yoshiyama et al., 2007; LasagnaReeves et al., 2011; de Calignon et al., 2012; Cohen et al., 2013), as well as in AD patients (Braak…”
BackgroundCorticobasal degeneration: a pathologically distinct 4R tauopathy
Kouri, N., Whitwell, J. L., Josephs, K. A., Rademakers, R., & Dickson, D. W. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.43 · Cited by 246
Experimental evidence for the age dependence of tau protein spread in the brain
Wegmann, S., Bennett, R. E., Delorme, L., Robbins, A. B., Hu, M., MacKenzie, D., Kirk, M. J., Schiantarelli, J., Tunio, N., Amaral, A. C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw6404 · Cited by 144
Kimura, T., Yamashita, S., Fukuda, T., Park, J., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., & Takashima, A. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601917 · Cited by 144
“Taken together, the accumulation of hyper- phosphorylated tau and synapse loss in aged mice, leading to inhibition of neural activity in parahippocampal areas, including the entorhinal cortex, may underlie place learn- ing impairment.”
BackgroundTau: From research to clinical development
Holtzman, D. M., Carrillo, M. C., Hendrix, J. A., Bain, L. J., Catafau, A. M., Gault, L. M., Goedert, M., Mandelkow, E., Mandelkow, E., Miller, D. S., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.018 · Cited by 139
Iijima, K., Gatt, A., & Iijima-Ando, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq200 · Cited by 96
“These results suggest that Drosophila models of tauopathies may recapitulate early pre-tangle events in tau-associated neurodegeneration (58).”
ResultBrunden, K. R., Ballatore, C., Crowe, A., Smith, Lee, V. M.-Y., & Trojanowski, J. Q. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.031 · Cited by 93
Self-citationFTDP-17 Tau Mutations Induce Distinct Effects on Aggregation and Microtubule Interactions
Combs, B., & Gamblin, T. C. (2012) · Biochemistry · doi:10.1021/bi3010818 · Cited by 79
“Many of the mutations cause increased propensities for aggregation and decreased microtubule interactions which could represent toxic gain and loss of functions respectively (13, 22–31), Several of the mutations have also been utilized in a diverse set of model organisms, including nematodes, flies, Xenopus, and mice…”
BackgroundIijima-Ando, K., Zhao, L., Gatt, A., Shenton, C., & Iijima, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq068 · Cited by 72
Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy
Takashima, A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14403 · Cited by 40
“…and understanding the mechanisms underlying NFT formation may lead to new strategies for preventing tauopathy-associated dementias [11,14–16, 24– 26, Although most mouse models of FTDP-17 mutant tau exhibit NFTs, neuronal loss, and behavioral deficits, one model does not: 12-month-old mice…”
Cell type-specific processing of human Tau proteins in Drosophila
Grammenoudi, S., Kosmidis, S., & Skoulakis, E. M. C. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.045 · Cited by 29
Tau pathology and neurodegeneration: An obvious but misunderstood link
Delacourte, A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14412 · Cited by 18
“Transgenic mice with tau mutations are modelingfamilial tau lesions, but are the phenotypic defects resulting from these models really relevant of familial tauopathies [29, 35]?”
Crowe, S. E., & Ellis‐Davies, G. C. R. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23306 · Cited by 15
Metadata
- Authors
- Lee, V. M.-Y., Kenyon, T. K., & Trojanowski, J. Q.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 1739
- Issue
- 2-3
- Pages
- 251-259
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2066502884
- Cited by
- 136
- References
- 9
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.